Redcare Pharmacy (RDC) Trading Update summary

Q3 performance highlights

• Group sales rose 21% year-over-year to €574M in Q3, with year-to-date sales up 34% to €1.7B.

• Non-Rx sales increased 20% year-over-year to €383M in Q3, with year-to-date growth of 20% to €1.2B.

• Rx sales in Germany surged 81% year-over-year to €69M in Q3, with September growth at 108%.

• Active customer base increased by 0.4M in Q3, reaching 11.9M, up 1.4M year-over-year.

• DACH segment Q3 sales reached €469M, with Rx sales up 22.6% and non-Rx up 19%.

E-Rx strategy and growth

• E-Rx sales growth accelerated from 7% in Q1 to 81% in Q3, peaking at 108% in September.

• Strong inflow from new customers purchasing e-Rx and conversion of existing non-Rx customers to e-Rx.

• Nationwide adoption of e-Rx and CardLink go-live contributed to growth.

• Decision made to accelerate Rx marketing investments due to positive eRx metrics and digital adoption.

• Accelerated marketing investment planned for Q4 to capitalize on e-Rx growth.

Customer experience and digital adoption

• Redcare's app is the top pharmacy app in Germany, rated 4.8 on iOS and 4.7 on Android.

• High customer satisfaction and NPS for e-Rx, comparable to overall German scores.

• E-Rx basket value is nearly double that of non-Rx, with strong repeat order rates.

• Digital convenience and NFC usage have significantly boosted customer repeat order rates.

• E-Rx customers show a strong mix of Rx, OTC, and BPC products.